厄贝沙坦联合阿托伐他汀治疗原发性高血压80例临床研究

Clinical research of erbesartan combined with atorvastatin in the treatment of 80 patients with primary hypertension

目的探讨联合应用降压药物厄贝沙坦和调脂药物阿托代他汀治疗原发性高血压的临床疗效。方法将160例原发性高血压患者随机分成对照组和观察组各80例。对照组单纯给予厄贝沙坦或加用硝苯地平缓释片治疗,观察组在此基础上加用阿托伐他汀片治疗。6个月后对比分析两组的动态血压、血脂、血尿酸。结果两组患者血压均得到有效控制,治疗6个月后两组24 h平均收缩压(24hSBp)及24 h平均舒张压(24hDBp)差异无统计学意义(P>0.05);观察组24 h平均压(24hpp)及血脂水平均低于对照组(P<0.05)。结论联合应用降压药物厄贝沙坦和调脂药物阿托代他汀治疗原发性高血压能有效降低患者24 h平均压及血尿酸,从而更有效地保护靶器官。

Objective To explore the clinical efficacy of erbesartan combined with atorvastatin in the treatment of primary hypertension. Methods 160 patients with primary hypertension were randomly divided into control group and observation group, 80 cases in each group. The control group was given erbesartan or nifedipine sustained-release tablets in addition, while the observation group was given atorvastatin on the basic therapy of control group. After 6 months of treatment, ambulatory blood pressure, serum lipids, blood uric acid were analyzed and compared. Results After 6 months of treatment, the blood pressure were control effectively. Before and after treatment the patient blood pressure was controlled effectively. There were no significant difference between 24hSPp and 24hDBp of the two groups above （ P 〉 0.05 ）. 24hpp and blood liquid level of the observation group were significantly lower than that of the control group （P 〈 0.05）. Conclusion It＇s helpful using erbesartan combined with atorvastatin to decrease 24hpp and blood uric acid of patients with primary hypertension, so as to protect the target organ of hypertension effectively.